176 related articles for article (PubMed ID: 21571382)
1. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study.
van Loon J; Offermann C; Ollers M; van Elmpt W; Vegt E; Rahmy A; Dingemans AM; Lambin P; De Ruysscher D
Radiother Oncol; 2011 May; 99(2):172-5. PubMed ID: 21571382
[TBL] [Abstract][Full Text] [Related]
2. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
van Loon J; De Ruysscher D; Wanders R; Boersma L; Simons J; Oellers M; Dingemans AM; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Teule J; Rhami A; Thimister W; Snoep G; Dehing-Oberije C; Lambin P
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):329-36. PubMed ID: 19782478
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
5. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.
Oh JR; Seo JH; Chong A; Min JJ; Song HC; Kim YC; Bom HS
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):925-35. PubMed ID: 22270509
[TBL] [Abstract][Full Text] [Related]
6. Extra-thoracic tumor burden but not thoracic tumor burden on (18)F-FDG PET/CT is an independent prognostic biomarker for extensive-disease small cell lung cancer.
Oh JR; Seo JH; Hong CM; Jeong SY; Lee SW; Lee J; Min JJ; Song HC; Bom HS; Kim YC; Ahn BC
Lung Cancer; 2013 Aug; 81(2):218-25. PubMed ID: 23731740
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
[TBL] [Abstract][Full Text] [Related]
9. Temporal lung tumor volume changes in small-cell lung cancer patients undergoing chemoradiotherapy.
Yee D; Rathee S; Robinson D; Murray B
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):142-7. PubMed ID: 20646851
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy.
Soussan M; Chouahnia K; Maisonobe JA; Boubaya M; Eder V; Morère JF; Buvat I
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):668-76. PubMed ID: 23306807
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
13. Should patient setup in lung cancer be based on the primary tumor? An analysis of tumor coverage and normal tissue dose using repeated positron emission tomography/computed tomography imaging.
van Elmpt W; Öllers M; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):379-85. PubMed ID: 21093173
[TBL] [Abstract][Full Text] [Related]
14. Nodal metabolic tumour volume on baseline
Alipour R; Bucknell N; Bressel M; Everitt S; MacManus M; Siva S; Hofman MS; Akhurst T; Hicks RJ; Iravani A
J Med Imaging Radiat Oncol; 2021 Oct; 65(6):748-754. PubMed ID: 34318603
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer.
Shirvani SM; Komaki R; Heymach JV; Fossella FV; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e91-7. PubMed ID: 21489716
[TBL] [Abstract][Full Text] [Related]
16. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
[TBL] [Abstract][Full Text] [Related]
17. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
19. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
20. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
